Commonly, this type of tumor does not respond to anti-PD-1/PD-L1 monoclonal antibodies, while blocking TGF-β signaling can significantly reverse the therapeutic resistance of PD-1/PD-L1 blockade therapy and enhance anti-tumor immunotherapy effects (19–22). Here, TGFB1 is linked to neoplasm.